Sionna Therapeutics initiated with a Sector Perform at RBC Capital

RBC Capital analyst Brian Abrahams initiated coverage of Sionna Therapeutics (SION) with a Sector Perform rating and $22 price target The company’s CFTR modulators could position it as a long-term key player in the cystic fibrosis space, the analyst tells investors in a research note. However, existing treatments create a high bar and there are questions as to how meaningfully de-risking Sionna’s next set of clinical data in mid-2026 will be, the analyst tells investors in a research note. As such, RBC would wait for more progress before stepping into the shares.